<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00712530</url>
  </required_header>
  <id_info>
    <org_study_id>GIHU004</org_study_id>
    <nct_id>NCT00712530</nct_id>
  </id_info>
  <brief_title>Single DermaVir Immunization in HIV-1 Infected Patients on HAART</brief_title>
  <acronym>GIHU004</acronym>
  <official_title>A Phase I Study to Evaluate the Tolerability and Safety of LC002, a DermaVir Vaccine, in HIV-1-infected Subjects Currently Under Treatment With Highly Active Antiretroviral Therapy (HAART)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genetic Immunity</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genetic Immunity</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  DermaVir is a plasmid DNA-containing synthetic nanomedicine. It is administered
           topically with DermaPrep to target Langerhans cells. Langerhans cells with DermaVir
           migrate to lymph nodes and express HIV-like particles that induce immune responses to
           kill HIV-infected cells.

        -  Hypothesis: Single DermaVir immunization is safe and immunogenic measured by induction
           of HIV-specific precursor/memory T cell responses.

        -  GIHU004 was a phase I dose escalation study conducted in Hungary. It evaluated the
           safety and immunogenicity of three dosing regimens of topical DermaVir immunization for
           the treatment of HIV-infected individuals on fully suppressive highly active
           antiretroviral therapy (HAART).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study enrolled nine HIV-infected adult subjects in three sequential dose cohorts. All
      had durable suppression of HIV-RNA on HAART over the previous 6 months and CD4 count over 300
      cells/mm3. Subjects, received on study Day 0 a single DermaVir immunization:

        -  Low dose: 0.1 mg pDNA, 0.8 mL DermaVir administered under two DermaPrep patches.

        -  Medium dose: 0.4 mg pDNA, 3.2 mL DermaVir administered under four DermaPrep patches.

        -  High dose: 0.8 mg pDNA, 6.4 mL DermaVir administered under eight DermaPrep patches.

      Subjects were on study for a total of 28 days followed by a post-treatment safety follow-up
      for 48 weeks. HAART was not interrupted. All subjects completed the 28-day treatment and 48
      weeks safety follow up phase.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Grade 3 Adverse Event Related to DermaVir Treatment</measure>
    <time_frame>28 days</time_frame>
    <description>Occurrence of at least one grade 3 or higher adverse event including signs/symptoms, laboratory toxicities and clinical events possibly, probably or definitely related to study treatment as judged by the Principal Investigator or the site investigators during the 28 days after DermaVir administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CD4+ T Cell Counts/mm3</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Detectable Anti-ds Antibody and ANA</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Having More Than 50 Copies/mL HIV RNA</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HIV-specific Memory T Cell Responses at Day 28 Compare to Baseline</measure>
    <time_frame>28 days</time_frame>
    <description>HIV-specific T cell precursors with high proliferative capacity (PHPC) were quantified as described earlier [Calarota et al. J Immunol 2008]. Gag-, Tat- and Rev-specific T cells were measured representing ca. 25% of HIV epitopes included in DermaVir.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in HIV-specific Memory T Cell Responses at Week 48</measure>
    <time_frame>48 weeks</time_frame>
    <description>HIV-specific T cell precursors with high proliferative capacity (PHPC) were quantified as described earlier [Calarota et al. J Immunol 2008]. Gag-, Tat- and Rev-specific T cells were measured representing ca. 25% of HIV epitopes included in DermaVir.
Note, group Single low-dose was measured at 24 weeks, for this group the 48 weeks data is not available</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single low-dose DermaVir immunization
0.1 mg pDNA/subject, 0.8 mL total volume of DermaVir
Administered topically with DermaPrep under two skin patches (0.4 mL/patch)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single medium-dose DermaVir immunization
0.4 mg pDNA/subject, 3.2 mL total volume of DermaVir
Administered topically with DermaPrep under four skin patches (0.8 mL/patch)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single high-dose DermaVir immunization
0.8 mg pDNA/subject, 6.4 mL total volume of DermaVir
Administered topically with DermaPrep under eight skin patches (0.4 mL/patch)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DermaVir</intervention_name>
    <description>DermaVir is a synthetic pathogen-like nanomedicine. The active pharmaceutical ingredient is a plasmid DNA expressing fifteen HIV proteins that assemble into HIV-like particles. These particles are safe, cannot replicate, integrate or reverse transcribed. DermaVir is targeted to Langerhans cells with DermaPrep medical device. These DermaVir-containing Langerhans cells migrate to the lymph nodes, where induce HIV-specific cytotoxic T cells that can recognize and kill HIV-infected cells.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>LC002</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HAART</intervention_name>
    <description>Three or more antiretroviral drugs that can fully suppress HIV RNA</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>Highly active antiretroviral therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability and willingness of subject or legal guardian/representative to give written
             informed consent

          -  HIV-1 infection, as documented by any licensed ELISA test kit and confirmed by Western
             blot, HIV-1 culture, HIV-1 antigen, plasma HIV-1 RNA, or a second antibody test by a
             method other than ELISA

          -  On a stable antiretroviral regimen without changes or interruptions for at least 12
             weeks prior to study entry

          -  Plasma HIV-1 RNA level of less than 50 copies/mL, obtained at least twice within the
             12 weeks prior to study entry

          -  Peak plasma HIV-1 RNA level before initiation of HAART &gt; 1000 copies/mL

          -  CD4 cell count &gt; 300 cells/mm3 within the 12 weeks prior to study entry

          -  Nadir (lowest) CD4+ cell count &gt; 250 cells/mm3 at any time prior to study entry

          -  The following laboratory values, obtained within 30 days prior to study entry:

               -  Absolute neutrophil count (ANC) &gt; 1000/mm3

               -  Hemoglobin &gt; 9.0 g/dL

               -  Platelet count &gt; 50,000/mm3

               -  Serum creatinine &lt; upper limit of the laboratory normal range (ULN)

               -  AST (SGOT), ALT (SGPT), and alkaline phosphatase &lt; 2.5 x ULN

               -  Total bilirubin &lt; 2.5 x ULN

               -  Anti-nuclear antibody (ANA) titer of 1:40 or lower and negative for serum
                  anti-double-stranded DNA antibody (anti-ds-DNA) test result at screening.

          -  All women of reproductive potential must have a negative urine beta-HCG pregnancy test
             performed within 14 days prior to study entry.

          -  Female study volunteers who are not of reproductive potential or whose male partner
             has undergone successful vasectomy are eligible without requiring the use of
             contraception. Acceptable documentation of menopause, sterilization, and azoospermia
             is written or oral documentation communicated by clinician.

          -  All subjects must not participate in a conception process (e.g. active attempt to
             become pregnant or to impregnate, sperm donation, in vitro fertilization) and, if
             participating in sexual activity that could lead to pregnancy, the study volunteer/
             partner must use two reliable methods of contraception simultaneously while receiving
             the protocol-specified vaccination and for 3 months after the last vaccination.

          -  Karnofsky performance score &gt; 90 within 30 days prior to study entry

          -  Men and women age 18-50 years

        Exclusion Criteria:

          -  Viral load measurement &gt; 50 copies/mL within the last 12 weeks prior to study entry

          -  History of or evidence of active skin disease (e.g. atopic dermatitis), chronic
             autoimmune disease or any other significant active skin disease

          -  Treatment with topical corticosteroids in close proximity to the proposed vaccination
             sites within 2 weeks prior to study entry

          -  Excessive exposure to the sun (e.g. sunbathing) within 2 weeks prior to study entry

          -  Use of any local skin treatments to the targeted vaccination sites within 7 days prior
             to study entry

          -  History of diabetes and bleeding disorders

          -  Previous CDC category C event

          -  Pregnancy or breast-feeding

          -  Use of immunomodulating therapy, including cyclosporin, IgG-containing products,
             interleukins, interferons, systemic glucocorticosteroids, or exposure to an
             experimental HIV vaccine within 6 months prior to study entry

          -  Receipt of any vaccine within 30 days prior to study entry

          -  Allergy/sensitivity to study vaccine products, including adhesives, will be excluded

          -  Active drug or alcohol use or dependence

          -  Serious illness until subject either completes therapy or is clinically stable on
             therapy, in the opinion of the site investigator, for at least 14 days prior to study
             entry

          -  Hepatitis B surface antigen and/or anti-hepatitis C positive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denes Banhegyi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Laszlo Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Saint Laszlo Hospital</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <link>
    <url>http://www.geneticimmunity.com</url>
    <description>Genetic Immunity's homepage</description>
  </link>
  <reference>
    <citation>Lőrincz O, Tőke ER, Somogyi E, Horkay F, Chandran PL, Douglas JF, Szebeni J, Lisziewicz J. Structure and biological activity of pathogen-like synthetic nanomedicines. Nanomedicine. 2012 May;8(4):497-506. doi: 10.1016/j.nano.2011.07.013. Epub 2011 Aug 10.</citation>
    <PMID>21839051</PMID>
  </reference>
  <reference>
    <citation>Somogyi E, Xu J, Gudics A, Tóth J, Kovács AL, Lori F, Lisziewicz J. A plasmid DNA immunogen expressing fifteen protein antigens and complex virus-like particles (VLP+) mimicking naturally occurring HIV. Vaccine. 2011 Jan 17;29(4):744-53. doi: 10.1016/j.vaccine.2010.11.019. Epub 2010 Nov 23.</citation>
    <PMID>21109034</PMID>
  </reference>
  <reference>
    <citation>Toke ER, Lorincz O, Somogyi E, Lisziewicz J. Rational development of a stable liquid formulation for nanomedicine products. Int J Pharm. 2010 Jun 15;392(1-2):261-7. doi: 10.1016/j.ijpharm.2010.03.048. Epub 2010 Mar 25.</citation>
    <PMID>20347027</PMID>
  </reference>
  <reference>
    <citation>Calarota SA, Foli A, Maserati R, Baldanti F, Paolucci S, Young MA, Tsoukas CM, Lisziewicz J, Lori F. HIV-1-specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals. J Immunol. 2008 May 1;180(9):5907-15.</citation>
    <PMID>18424710</PMID>
  </reference>
  <results_reference>
    <citation>Lisziewicz J, Bakare N, Calarota SA, Bánhegyi D, Szlávik J, Ujhelyi E, Tőke ER, Molnár L, Lisziewicz Z, Autran B, Lori F. Single DermaVir immunization: dose-dependent expansion of precursor/memory T cells against all HIV antigens in HIV-1 infected individuals. PLoS One. 2012;7(5):e35416. doi: 10.1371/journal.pone.0035416. Epub 2012 May 9.</citation>
    <PMID>22590502</PMID>
  </results_reference>
  <results_reference>
    <citation>Lisziewicz J, Tőke ER. Nanomedicine applications towards the cure of HIV. Nanomedicine. 2013 Jan;9(1):28-38. doi: 10.1016/j.nano.2012.05.012. Epub 2012 May 30. Review.</citation>
    <PMID>22659241</PMID>
  </results_reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 4, 2008</study_first_submitted>
  <study_first_submitted_qc>July 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2008</study_first_posted>
  <results_first_submitted>February 19, 2013</results_first_submitted>
  <results_first_submitted_qc>February 19, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 26, 2013</results_first_posted>
  <last_update_submitted>February 19, 2013</last_update_submitted>
  <last_update_submitted_qc>February 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Immune Therapy</keyword>
  <keyword>DermaVir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Nine subjects were sequentially enrolled into each cohort. Participants were recruited from the Szent László Hospital, Budapest, Hungary.</recruitment_details>
      <pre_assignment_details>The first three subjects received a single low-dose DermaVir immunization. Further enrolment of subjects into the medium and high dose cohorts began only after the safety data for cohorts low and medium doses, respectively were available, and the criteria for enrolling into the next cohort were met.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Single Low-dose (0.1 mg pDNA/Subject) DermaVir Immunization</title>
          <description>Single low-dose DermaVir immunization
0.1 mg pDNA/subject, 0.8 mL total volume of DermaVir
Administered topically with DermaPrep under two skin patches (0.4 mL/patch)</description>
        </group>
        <group group_id="P2">
          <title>Single Medium-dose (0.4 mg pDNA/Subject) DermaVir Immunization</title>
          <description>Single medium-dose DermaVir immunization
0.4 mg pDNA/subject, 3.2 mL total volume of DermaVir
Administered topically with DermaPrep under four skin patches (0.8 mL/patch)</description>
        </group>
        <group group_id="P3">
          <title>Single High-dose (0.8 mg pDNA/Subject) DermaVir Immunization</title>
          <description>Single high-dose DermaVir immunization
0.8 mg pDNA/subject, 6.4 mL total volume of DermaVir
Administered topically with DermaPrep under eight skin patches (0.4 mL/patch)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3">Screened 4 patients, but one failed to meet entry criteria due to a history of bleeding and diabetes</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single Low-dose (0.1 mg pDNA/Subject) DermaVir Immunization</title>
          <description>Single low-dose DermaVir immunization
0.1 mg pDNA/subject, 0.8 mL total volume of DermaVir
Administered topically with DermaPrep under two skin patches (0.4 mL/patch)</description>
        </group>
        <group group_id="B2">
          <title>Single Medium-dose (0.4 mg pDNA/Subject) DermaVir Immunization</title>
          <description>Single medium-dose DermaVir immunization
0.4 mg pDNA/subject, 3.2 mL total volume of DermaVir
Administered topically with DermaPrep under four skin patches (0.8 mL/patch)</description>
        </group>
        <group group_id="B3">
          <title>Single High-dose (0.8 mg pDNA/Subject) DermaVir Immunization</title>
          <description>Single high-dose DermaVir immunization
0.8 mg pDNA/subject, 6.4 mL total volume of DermaVir
Administered topically with DermaPrep under eight skin patches (0.4 mL/patch)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" spread="4.3"/>
                    <measurement group_id="B2" value="34" spread="4.0"/>
                    <measurement group_id="B3" value="36" spread="9.0"/>
                    <measurement group_id="B4" value="38" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Grade 3 Adverse Event Related to DermaVir Treatment</title>
        <description>Occurrence of at least one grade 3 or higher adverse event including signs/symptoms, laboratory toxicities and clinical events possibly, probably or definitely related to study treatment as judged by the Principal Investigator or the site investigators during the 28 days after DermaVir administration.</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Low-dose (0.1 mg pDNA/Subject) DermaVir Immunization</title>
            <description>Single low-dose DermaVir immunization
0.1 mg pDNA/subject, 0.8 mL total volume of DermaVir
Administered topically with DermaPrep under two skin patches (0.4 mL/patch)</description>
          </group>
          <group group_id="O2">
            <title>Single Medium-dose (0.4 mg pDNA/Subject) DermaVir Immunization</title>
            <description>Single medium-dose DermaVir immunization
0.4 mg pDNA/subject, 3.2 mL total volume of DermaVir
Administered topically with DermaPrep under four skin patches (0.8 mL/patch)</description>
          </group>
          <group group_id="O3">
            <title>Single High-dose (0.8 mg pDNA/Subject) DermaVir Immunization</title>
            <description>Single high-dose DermaVir immunization
0.8 mg pDNA/subject, 6.4 mL total volume of DermaVir
Administered topically with DermaPrep under eight skin patches (0.4 mL/patch)</description>
          </group>
        </group_list>
        <measure>
          <title>Grade 3 Adverse Event Related to DermaVir Treatment</title>
          <description>Occurrence of at least one grade 3 or higher adverse event including signs/symptoms, laboratory toxicities and clinical events possibly, probably or definitely related to study treatment as judged by the Principal Investigator or the site investigators during the 28 days after DermaVir administration.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD4+ T Cell Counts/mm3</title>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Low-dose (0.1 mg pDNA/Subject) DermaVir Immunization</title>
            <description>Single low-dose DermaVir immunization
0.1 mg pDNA/subject, 0.8 mL total volume of DermaVir
Administered topically with DermaPrep under two skin patches (0.4 mL/patch)</description>
          </group>
          <group group_id="O2">
            <title>Single Medium-dose (0.4 mg pDNA/Subject) DermaVir Immunization</title>
            <description>Single medium-dose DermaVir immunization
0.4 mg pDNA/subject, 3.2 mL total volume of DermaVir
Administered topically with DermaPrep under four skin patches (0.8 mL/patch)</description>
          </group>
          <group group_id="O3">
            <title>Single High-dose (0.8 mg pDNA/Subject) DermaVir Immunization</title>
            <description>Single high-dose DermaVir immunization
0.8 mg pDNA/subject, 6.4 mL total volume of DermaVir
Administered topically with DermaPrep under eight skin patches (0.4 mL/patch)</description>
          </group>
        </group_list>
        <measure>
          <title>CD4+ T Cell Counts/mm3</title>
          <units>CD4+ T cell counts/mm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="893" spread="461"/>
                    <measurement group_id="O2" value="845" spread="68"/>
                    <measurement group_id="O3" value="621" spread="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Detectable Anti-ds Antibody and ANA</title>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Low-dose (0.1 mg pDNA/Subject) DermaVir Immunization</title>
            <description>Single low-dose DermaVir immunization
0.1 mg pDNA/subject, 0.8 mL total volume of DermaVir
Administered topically with DermaPrep under two skin patches (0.4 mL/patch)</description>
          </group>
          <group group_id="O2">
            <title>Single Medium-dose (0.4 mg pDNA/Subject) DermaVir Immunization</title>
            <description>Single medium-dose DermaVir immunization
0.4 mg pDNA/subject, 3.2 mL total volume of DermaVir
Administered topically with DermaPrep under four skin patches (0.8 mL/patch)</description>
          </group>
          <group group_id="O3">
            <title>Single High-dose (0.8 mg pDNA/Subject) DermaVir Immunization</title>
            <description>Single high-dose DermaVir immunization
0.8 mg pDNA/subject, 6.4 mL total volume of DermaVir
Administered topically with DermaPrep under eight skin patches (0.4 mL/patch)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Detectable Anti-ds Antibody and ANA</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Having More Than 50 Copies/mL HIV RNA</title>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Low-dose (0.1 mg pDNA/Subject) DermaVir Immunization</title>
            <description>Single low-dose DermaVir immunization
0.1 mg pDNA/subject, 0.8 mL total volume of DermaVir
Administered topically with DermaPrep under two skin patches (0.4 mL/patch)</description>
          </group>
          <group group_id="O2">
            <title>Single Medium-dose (0.4 mg pDNA/Subject) DermaVir Immunization</title>
            <description>Single medium-dose DermaVir immunization
0.4 mg pDNA/subject, 3.2 mL total volume of DermaVir
Administered topically with DermaPrep under four skin patches (0.8 mL/patch)</description>
          </group>
          <group group_id="O3">
            <title>Single High-dose (0.8 mg pDNA/Subject) DermaVir Immunization</title>
            <description>Single high-dose DermaVir immunization
0.8 mg pDNA/subject, 6.4 mL total volume of DermaVir
Administered topically with DermaPrep under eight skin patches (0.4 mL/patch)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Having More Than 50 Copies/mL HIV RNA</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HIV-specific Memory T Cell Responses at Day 28 Compare to Baseline</title>
        <description>HIV-specific T cell precursors with high proliferative capacity (PHPC) were quantified as described earlier [Calarota et al. J Immunol 2008]. Gag-, Tat- and Rev-specific T cells were measured representing ca. 25% of HIV epitopes included in DermaVir.</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Low-dose (0.1 mg pDNA/Subject) DermaVir Immunization</title>
            <description>Single low-dose DermaVir immunization
0.1 mg pDNA/subject, 0.8 mL total volume of DermaVir
Administered topically with DermaPrep under two skin patches (0.4 mL/patch)</description>
          </group>
          <group group_id="O2">
            <title>Single Medium-dose (0.4 mg pDNA/Subject) DermaVir Immunization</title>
            <description>Single medium-dose DermaVir immunization
0.4 mg pDNA/subject, 3.2 mL total volume of DermaVir
Administered topically with DermaPrep under four skin patches (0.8 mL/patch)</description>
          </group>
          <group group_id="O3">
            <title>Single High-dose (0.8 mg pDNA/Subject) DermaVir Immunization</title>
            <description>Single high-dose DermaVir immunization
0.8 mg pDNA/subject, 6.4 mL total volume of DermaVir
Administered topically with DermaPrep under eight skin patches (0.4 mL/patch)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HIV-specific Memory T Cell Responses at Day 28 Compare to Baseline</title>
          <description>HIV-specific T cell precursors with high proliferative capacity (PHPC) were quantified as described earlier [Calarota et al. J Immunol 2008]. Gag-, Tat- and Rev-specific T cells were measured representing ca. 25% of HIV epitopes included in DermaVir.</description>
          <units>PHPC count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="325" spread="266"/>
                    <measurement group_id="O2" value="136202" spread="162287"/>
                    <measurement group_id="O3" value="50759" spread="44792"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in HIV-specific Memory T Cell Responses at Week 48</title>
        <description>HIV-specific T cell precursors with high proliferative capacity (PHPC) were quantified as described earlier [Calarota et al. J Immunol 2008]. Gag-, Tat- and Rev-specific T cells were measured representing ca. 25% of HIV epitopes included in DermaVir.
Note, group Single low-dose was measured at 24 weeks, for this group the 48 weeks data is not available</description>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Low-dose (0.1 mg pDNA/Subject) DermaVir Immunization</title>
            <description>Single low-dose DermaVir immunization
0.1 mg pDNA/subject, 0.8 mL total volume of DermaVir
Administered topically with DermaPrep under two skin patches (0.4 mL/patch)</description>
          </group>
          <group group_id="O2">
            <title>Single Medium-dose (0.4 mg pDNA/Subject) DermaVir Immunization</title>
            <description>Single medium-dose DermaVir immunization
0.4 mg pDNA/subject, 3.2 mL total volume of DermaVir
Administered topically with DermaPrep under four skin patches (0.8 mL/patch)</description>
          </group>
          <group group_id="O3">
            <title>Single High-dose (0.8 mg pDNA/Subject) DermaVir Immunization</title>
            <description>Single high-dose DermaVir immunization
0.8 mg pDNA/subject, 6.4 mL total volume of DermaVir
Administered topically with DermaPrep under eight skin patches (0.4 mL/patch)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HIV-specific Memory T Cell Responses at Week 48</title>
          <description>HIV-specific T cell precursors with high proliferative capacity (PHPC) were quantified as described earlier [Calarota et al. J Immunol 2008]. Gag-, Tat- and Rev-specific T cells were measured representing ca. 25% of HIV epitopes included in DermaVir.
Note, group Single low-dose was measured at 24 weeks, for this group the 48 weeks data is not available</description>
          <units>PHPC count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3899" spread="869"/>
                    <measurement group_id="O2" value="9878" spread="10257"/>
                    <measurement group_id="O3" value="18382" spread="21477"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From start of study vaccination to study closure</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Single Low-dose (0.1 mg pDNA/Subject) DermaVir Immunization</title>
          <description>Single low-dose DermaVir immunization
0.1 mg pDNA/subject, 0.8 mL total volume of DermaVir
Administered topically with DermaPrep under two skin patches (0.4 mL/patch)</description>
        </group>
        <group group_id="E2">
          <title>Single Medium-dose (0.4 mg pDNA/Subject) DermaVir Immunization</title>
          <description>Single medium-dose DermaVir immunization
0.4 mg pDNA/subject, 3.2 mL total volume of DermaVir
Administered topically with DermaPrep under four skin patches (0.8 mL/patch)</description>
        </group>
        <group group_id="E3">
          <title>Single High-dose (0.8 mg pDNA/Subject) DermaVir Immunization</title>
          <description>Single high-dose DermaVir immunization
0.8 mg pDNA/subject, 6.4 mL total volume of DermaVir
Administered topically with DermaPrep under eight skin patches (0.4 mL/patch)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERBILIRUBINAEMY</sub_title>
                <description>Moderate</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>ELEVATED SE BILIRUBIN</sub_title>
                <description>Moderate</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>NAUSEA</sub_title>
                <description>Mild</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <description>Mild</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>FEVER</sub_title>
                <description>Mild, related to study medication</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <description>Mild, related to study medictaion</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>LUMBALGY</sub_title>
                <description>Mild, Not related to study medication</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>MYALGIAS</sub_title>
                <description>Mild,related to study medication</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PRURITUS</sub_title>
                <description>Mild</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>HYPERESTHESY ON THE SITES</sub_title>
                <description>Mild</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>MACULAR ERYTHEMA</sub_title>
                <description>Mild, non related to study medication</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This is a Phase I small sample study that was not powered for the secondary efficacy endpoints.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Denes Banhegyi</name_or_title>
      <organization>Szent Laszlo Hospital, Budapest, Hungary</organization>
      <phone>+3614558152</phone>
      <email>immunol@mail.datanet.hu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

